ACE2 and acute respiratory distress syndrome: A phase 2 trial of enzymatically active ACE2 in patients with ARDS, performed before the pandemic, failed to show a benefit in lung compliance, lung oxygenation, or Sequential Organ Failure Assessment score (51).